Campbell and Moorehead BMC Cancer 2011, 11:480 http://www.biomedcentral.com/1471-2407/11/480 754807, in a human rhabdomyosarcoma model. Cancer Res 2010, 70:7221-7231. 28. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, et al: Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008, 105:8387-8392. 29. Siegbahn A, Hammacher A, Westermark B, Heldin CH: Differential effects of the various isoforms of platelet-derived growth factor on chemotaxis of fibroblasts, monocytes, and granulocytes. J Clin Invest 1990, 85:916-920. 30. Vassbotn FS, Ostman A, Siegbahn A, Holmsen H, Heldin CH: Neomycin is a platelet-derived growth factor (PDGF) antagonist that allows discrimination of PDGF alpha- and beta-receptor signals in cells expressing both receptor types. J Biol Chem 1992, 267:15635-15641. 31. Wennstrom S, Siegbahn A, Yokote K, Arvidsson AK, Heldin CH, Mori S, et al: Membrane ruffling and chemotaxis transduced by the PDGF beta- receptor require the binding site for phosphatidylinositol 3’ kinase. Oncogene 1994, 9:651-660. 32. Ahmad A, Wang Z, Kong D, Ali R, Ali S, Banerjee S, et al: Platelet-derived growth factor-D contributes to aggressiveness of breast cancer cells by up-regulating Notch and NF-kappaB signaling pathways. Breast Cancer Res Treat 2011, 126:15-25. 33. Kang DW, Min dS: Platelet derived growth factor increases phospholipase D1 but not phospholipase D2 expression via NFkappaB signaling pathway and enhances invasion of breast cancer cells. Cancer Lett 2010, 294:125-133. 34. Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004, 15:275-286. 35. Ostman A, Heldin CH: PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007, 97:247-274. 36. Faraone D, Aguzzi MS, Toietta G, Facchiano AM, Facchiano F, Magenta A, et al: Platelet-derived growth factor-receptor alpha strongly inhibits melanoma growth in vitro and in vivo. Neoplasia 2009, 11:732-742. 37. McCarty MF, Somcio RJ, Stoeltzing O, Wey J, Fan F, Liu W, et al: Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content. J Clin Invest 2007, 117:2114-2122. 38. Rosenkranz S, Kazlauskas A: Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 1999, 16:201-216. 39. Brazil DP, Hemmings BA: Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001, 26:657-664. 40. Manning BD, Cantley LC: AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274. 41. Toker A, Yoeli-Lerner M: Akt signaling and cancer: surviving but not moving on. Cancer Res 2006, 66:3963-3966. 42. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, et al: The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/ HER2 inhibitors. Cancer Res 2009, 69:161-170. 43. Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, Ten EC, et al: Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924. Mol Cancer Ther 2011, 10:117-125. 44. Abraham J, Prajapati SI, Nishijo K, Schaffer BS, Taniguchi E, Kilcoyne A, et al: Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol Cancer Ther 2011, 10:697-707. 45. Campbell CI, Thompson DE, Siwicky MD, Moorehead RA: Murine mammary tumor cells with a claudin-low genotype. Cancer Cell International 2011, 11:28. 46. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al: Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007, 8:R76. 47. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12:R68. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/11/480/prepub Page 13 of 13 doi:10.1186/1471-2407-11-480 Cite this article as: Campbell and Moorehead: Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors. BMC Cancer 2011 11:480. Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color ﬁgure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit